Scientists figure out the flaw behind stuck rovers using free software
In 2005, the wheels of NASA's Mars Exploration Rover Opportunity were stuck in sand, and it took six weeks of inch-by-inch maneuvering by experts at the agency's Jet Propulsion Laboratory to free it. Just a few weeks ago, the Perseverance rover also struggled with a stuck drill bit, but the situation was fortunately resolved.
But not every story has a happy ending. In 2009, the Spirit rover found itself on a slope in a rather peculiar situation, and could never be recovered. With the Martian winter further complicating the rescue efforts, the Spirit mission was officially abandoned two years later. Such accidents could soon become a thing of the past.
A major breakthrough
Engineers at the University of Wisconsin–Madison have spotted a flaw in the testing protocols of these rovers on Earth, which often gives an overly optimistic view of their exploration capabilities. Rovers are often tested in desert-like areas, which simulate the dry conditions on the Moon and Mars, accounting for the reduced gravity on these bodies.
Recommended Videos
But as per the research team at UW-Madison, the tests often ignore the impact of gravity exerted on the sand particles, which means the simulation tests are not nearly as accurate (read: realistic) as they should be. 'An important element in preparing for these missions is an accurate understanding of how a rover will traverse extraterrestrial surfaces in low gravity to prevent it from getting stuck in soft terrain or rocky areas,' the team explains.
Notably, it's the same team that is working on simulation modeling for NASA's VIPER rover. The Volatiles Investigating Polar Exploration Rover, or VIPER, mission was supposed to look for water and other useful resources on the harsher side of the Moon, but the project was terminated in 2024.
The team relied on an open-source simulation software called Chrono to discover the discrepancy in the Earth-based rover testing protocols. It's the same software that is also used for estimating the off-roading capabilities of US Army vehicles. The team has detailed its findings in a paper published in the Journal of Field Robotics.
The road to safer rover missions
The team at UW-Madison, however, continued its work on rover tech for space missions. Elaborating on the phenomenon, the team notes that Earth's gravity creates a stronger pull on the sand particles than what the same particles would feel on the Moon, or Mars.
Additionally, the sand on Earth is said to be more rigid, while the top surface on the Moon is softer, which means it will shift more dramatically under the rover's wheels, and as a result, reduces the traction.
Interestingly, the software that enabled the aforementioned discovery, is used across diverse industries. Aside from educational institutions, some of its more notable users include the U.S. Army Ground Vehicle Systems Center, NASA's Jet Propulsion Lab, the U.S. Army Engineer Research and Development Center, and the National Renewable Energy Lab.
It was also used by the experts at the Politecnico di Milano in Italy for the Mascot lander for its asteroid Ryugu mission. In addition to vehicle simulations and advanced robots, Project Chrono has even been deployed for 'miniaturized mechanisms for watches.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
The 3 Things That Matter for CRISPR Therapeutics Now
Key Points CRISPR Therapeutics' gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company has plenty of money right now, but its expenses could grow quite a bit from here. 10 stocks we like better than CRISPR Therapeutics › Biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion. The company remains in the red largely because it's barely got any revenue to speak of. It's not likely to swing to a profit in the immediate future, either. Still, if you've got room in your portfolio for a little more risk paired with above-average upside potential, this is a stock worth adding to your watchlist (if not your portfolio) with three key things in mind. But first things first. What's CRISPR Therapeutics? Although the company was founded back in 2013, most of its time since then has been spent refining the work first done by Jennifer Doudna, Ph.D., and co-founder Emmanuelle Charpentier, Ph.D., who jointly figured out how to "edit" defective genetic code in a strand of DNA. By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short palindromic repeats -- or CRISPR -- medical science is now able to do what was once unthinkable. It's still early days for the science -- very early. In fact, the FDA only made its first-ever approval of a gene-editing therapy in December of 2023. That's Casgevy, for the treatment of sickle cell disease, which was approved in the U.K. only a month earlier. The thing is, Casgevy is CRISPR Therapeutics' treatment, underscoring how well developed this biotech outfit's science is, and perhaps indirectly underscoring the fact that many rival drug developers are still well behind. Casgevy isn't the company's proverbial big Kahuna, however -- it's merely proof that gene editing can be successfully done. The heavy hitters in CRISPR's developmental pipeline are CTX310 for the treatment of certain cardiovascular diseases, and CTX131 and CTX112, both of which are taking aim at cancer using the very same CRISPR science. Although all of these drugs still have years of developmental work ahead of them, again, the underlying gene-editing technology works. Its potential applications are enormous. That's why CRISPR has a dozen or so others in clinical or pre-clinical trials also underway at this time. Three things to watch As time marches on, though, this stock's backstory is evolving from one broadly driven by an idea to one that increasingly hinges on some very specific factors. To this end, here are the three things that matter the most to current and prospective CRISPR Therapeutics shareholders right now -- and for the foreseeable future -- since they'll either drive the stock higher or let it slide into a sell-off. 1. Insurers and patients' acceptance of CRISPR-based medicine's cost While the science of using CRISPR to repair faulty cells is exciting, it's not exactly cheap or easy. See, Casgevy isn't a pill or an injection. It requires a sample of a patient's own blood stem cells to create a completely customized therapy, which is then infused back into that patient after he or she has undergone chemotherapy. All of this care can only be done at one of CRISPR's 65 authorized treatment centers. Total cost? A little over $2 million per patient. That's pretty steep for any therapy, but particularly for sickle cell disease, which at least has a handful of more affordable treatment options. The cost of treating life-threatening cancer is less of a stumbling block, even for insurers that may occasionally see bills nearly this size for even the most conventional of oncology treatment regimens. The price tag of this and any other future CRISPR-based therapy, however, is likely to remain in this ballpark, where payers may well balk. 2. The ongoing development of CTX310 Again, while Casgevy is approved to treat sickle cell disease, it's really more of a proving ground for the other drugs in CRISPR Therapeutics' developmental pipeline. This, of course, includes CTX131 and CTX112, but the company itself is putting the spotlight on CTX310 as a treatment for ANGPTL3 (angiopoietin-like 3), which is often associated with poorly regulated cholesterol, lipids, and triglycerides. If the company can demonstrate its solution is at least as good as (if not better than) alternative cholesterol-fighting drugs, investors might continue to support this stock. This information is coming. The company posted encouraging early results of CTX310's phase 1 clinical trial late last month, and says it intends to offer more detailed data at a healthcare conference scheduled for later in the year. If it's compelling enough, it could tamp down worries over the high cost of any CRISPR-based treatment. 3. Liquidity Finally, you'll want to keep an eye on CRISPR Therapeutics' liquidity, or the amount of cash it has on hand to cover its operating costs while it continues to develop CTX310 at the same time it's looking to expand Casgevy's commercialization. As of the end of the first quarter, CRISPR was sitting on $1.86 billion in cash, which is a lot for a company of this size. It's working through this money pretty quickly, though, shelling out nearly $150 million in operating expenses in Q1 alone. That doesn't include a full quarter's worth of the sort of costs the phase 1 trial of CTX310 is incurring now, or any other trials it starts or expands in the foreseeable future. Continued revenue growth from Casgevy should seemingly help offset some of this spending, even if not all of it. Indeed, the analyst community expects CRISPR's top line to soar from less than $50 million this year to more than $400 million in 2027, even if these same analysts believe the company will still be well in the red then. A few years' worth of losses isn't exactly unusual for a young biotech start-up. CRISPR Therapeutics would still lack much-needed scale even after such growth, though. The money it needs to spend just to get any meaningful degree of traction from Casgevy or maintain its clinical trials could far exceed any conceivable amount of revenue the newly approved drug might produce in the foreseeable future. Don't confuse what CRSP stock is So what's the call? There isn't one -- not this time. Buying or avoiding a stake in CRISPR Therapeutics is entirely up to you, depending on your risk tolerances and your ability to manage such a holding. If you're strictly a buy-and-hold investor, there's probably not enough certainty here yet to latch onto for the long haul. And there may never be. If you've got a speculative side that can tolerate risk in exchange for hype-driven reward, though, you could make a decent bullish case. Just don't confuse the two, or muddy the waters by trying to be both. The last thing you want to do here is talk yourself into a long-term position that requires you to ignore obvious red flags like the three potential ones discussed above. Should you buy stock in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy. The 3 Things That Matter for CRISPR Therapeutics Now was originally published by The Motley Fool
Los Angeles Times
24 minutes ago
- Los Angeles Times
Perseid meteor shower: When it peaks and what could spoil the party
When it comes to meteor showers, the Perseids pop. It's not just about the quantity of meteors (as many as 100 per hour) and their showy quality (fireballs!) but also their superb timing. The annual shower hits its peak on warm, laid-back August nights as the Earth crosses paths with the dust cloud left by comet Swift-Tuttle on its every-133-years swing past our planet. Watching the shower can be an awesome experience as meteors streak past in the summertime heavens, leaving light and color in their wake. John Denver, 27 and on a camping trip amid the Colorado pines, was so moved after seeing the Perseids rain fire in the sky that he wrote 'Rocky Mountain High.' That said, this year there's a caveat. The meteor shower is set to peak the night of Aug. 11 and 12, according to Ed Krupp, director of L.A.'s Griffith Observatory. NASA says the best viewing time is in the predawn hours. But the moon will get in the way. 'The waning gibbous moon will severely compromise this shower at the time of maximum activity,' notes the American Meteor Society. The moon will be about 92% full and in the sky much of the time as the shower hits its peak, Krupp said. 'Fainter meteors will be lost in the moon's glow,' he told The Times. 'At its best, the Perseid shower delivers between 50 to 100 meteors per hour, but this year far fewer will be seen.' Stargazers can cross their fingers for more fireballs, a phenomenon that the Perseid shower is known for, according to NASA. 'Fireballs are larger explosions of light and color that can persist longer than an average meteor streak,' NASA says. 'This is due to the fact that fireballs originate from larger particles of cometary material.' Krupp advises that those who are 'committed to the Perseids' despite the diminished chances of visibility this year 'should go somewhere far from any urban center and away from the scattered glare of artificial lighting.' Experts advise booking campsites in Joshua Tree, the Mojave Desert and Anza-Borrego Desert State Park. There are multiple other good spots. Once there, aim for an expansive view because, although the Perseids seem to radiate from the northern constellation Perseus, they can appear anywhere, Bill Cooke, a NASA meteor scientist, told The Times in 2024. 'So get on a cot or on a sleeping bag,' he said, 'and lie flat on your back and look straight up.' Good news for 2026: The forecast for the Perseid meteor shower is excellent. The moon will be dark, and as NPR reports, an unusually large number of meteors are expected to flash through the night sky.
Medscape
24 minutes ago
- Medscape
More Sit-to-Stand Transitions Benefit Postmenopausal Women
TOPLINE: Reducing sedentary behavior with interventions such as increasing daily sit-to-stand transitions might help lower blood pressure in postmenopausal women with overweight or obesity. METHODOLOGY: Researchers conducted a randomized controlled trial to assess how different strategies to reduce time spent sitting affected the physiologic responses of postmenopausal women who led sedentary lives. The researchers included 407 women in the postmenopausal phase (mean age, 68 years; 92% White) who had overweight or obesity (average BMI, 32), had a sitting time of at least 7 hours a day, and performed no more than 70 sit-to-stand transitions daily. The women were randomly assigned to one of three study arms: healthy living (n = 135), sit less (n = 136), and increased sit-to-stand transitions (n = 136). All arms received seven sessions of individual health coaching over 12 weeks. Researchers assessed blood pressure and markers of glucose regulation using fasting blood samples. Readings from thigh- and hip-worn accelerometers for 7 days were used to evaluate posture, sedentary behavior, and physical activity. Primary outcomes were measurements of glucose regulation and resting blood pressure at baseline and 3 months. TAKEAWAY: A total of 388 women completed the trial, with no serious adverse events related to the study. Participants in the sit-less arm had a daily sitting time of approximately 58 minutes less than those in the healthy-living arm (P < .001), whereas those in the sit-to-stand arm had 26 more sit-to-stand transitions daily (P < .001). Diastolic blood pressure fell by 2.24 mm Hg in the sit-to-stand arm compared with the healthy living arm (P = .02); the decrease in systolic blood pressure did not reach a predefined significance level. Compared with the healthy-living arm, neither intervention produced significant changes in markers of glucose regulation. IN PRACTICE: 'Postmenopausal women are at high risk of engaging in large amounts of sitting time and cardiovascular diseases. The present randomized controlled trial adds to existing evidence by demonstrating that within just 3 months, increasing' sit-to-stand transitions can lower diastolic blood pressure, the researchers wrote. SOURCE: This study was led by Sheri J. Hartman, PhD, University of California, San Diego. It was published online on July 25, 2025, in Circulation. LIMITATIONS: The generalizability of findings was limited by the lack of ethnic and racial diversity. The 3-month intervention period may have been too brief to observe sizeable physiologic changes. Measurement of only fasting glucose parameters could not capture changes after meals. DISCLOSURES: This study received support from the National Institute of Aging. Additional support was provided by the Altman Clinical & Translational Research Institute at the University of California, San Diego, funded by the National Center for Advancing Translational Sciences. The authors did not report any conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
